Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study

In Myanmar, hepatitis C virus (HCV) infection prevalence is 2%. A combination therapy of pegylated interferon alfa-2a and ribavirin (PEG-IFNa/RBV) is a standard treatment, but the effect of this antiviral therapy needs evaluation as to determine the efficacy and safety of dual PEG-IFNa/RBV therapy i...

Descripción completa

Detalles Bibliográficos
Autores principales: Naing, Cho, Sitt, Than, Aung, Aye TD, Aung, Kyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
4900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554122/
https://www.ncbi.nlm.nih.gov/pubmed/26222859
http://dx.doi.org/10.1097/MD.0000000000001234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554122/
https://www.ncbi.nlm.nih.gov/pubmed/26222859
http://dx.doi.org/10.1097/MD.0000000000001234

Ejemplares similares